Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV specialist ViiV Healthcare in a deal that ...
The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...
Pfizer has relinquished its stake in ViiV Healthcare in a deal valued at just over $2.1 billion that ramps up Shionogi's ...
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...
Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback